Literature DB >> 21352213

5-HT(1D) receptor immunoreactivity in the sphenopalatine ganglion: implications for the efficacy of triptans in the treatment of autonomic signs associated with cluster headache.

Jason J Ivanusic1, Matthew M K Kwok1, Andrew H Ahn1, Ernest A Jennings1.   

Abstract

OBJECTIVE: To determine if 5-HT(1D) receptors are located in the sphenopalatine ganglion.
BACKGROUND: While the 5-HT(1D) receptor has been described in sensory and sympathetic ganglia in the head, it was not known whether they were also located in parasympathetic ganglia.
METHODS: We used retrograde labeling combined with immunohistochemistry to examine 5-HT(1D) receptor immunoreactivity in rat sphenopalatine ganglion neurons that project to the lacrimal gland, nasal mucosa, cerebral vasculature, and trigeminal ganglion.
RESULTS: We found 5-HT(1D) receptor immunoreactivity in nerve terminals around postganglionic cell bodies within the sphenopalatine ganglion. All 5-HT(1D) -immunoreactive terminals were also immunoreactive for calcitonin gene-related peptide but not vesicular acetylcholine transporter, suggesting that they were sensory and not preganglionic parasympathetic fibers. Our retrograde labeling studies showed that approximately 30% of sphenopalatine ganglion neurons innervating the lacrimal gland, 23% innervating the nasal mucosa, and 39% innervating the trigeminal ganglion were in apparent contact with 5-HT(1D) receptor containing nerve terminals.
CONCLUSION: These data suggest that 5-HT(1D) receptors within primary afferent neurons that innervate the sphenopalatine ganglion are in a position to modulate the excitability of postganglionic parasympathetic neurons that innervate the lacrimal gland and nasal mucosa, as well as the trigeminal ganglion. This has implications for triptan (5-HT(1D) receptor agonist) actions on parasympathetic symptoms in cluster headache.
© 2011 American Headache Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21352213      PMCID: PMC3073163          DOI: 10.1111/j.1526-4610.2011.01843.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  37 in total

1.  Vesicular acetylcholine transporter (VAChT) protein: a novel and unique marker for cholinergic neurons in the central and peripheral nervous systems.

Authors:  U Arvidsson; M Riedl; R Elde; B Meister
Journal:  J Comp Neurol       Date:  1997-02-24       Impact factor: 3.215

2.  Ultrastructural identification of trigeminal nerve terminals in the pterygopalatine ganglion of rats: an anterograde tracing and immunohistochemical study.

Authors:  H J Beckers; J Klooster; G F Vrensen; W P Lamers
Journal:  Brain Res       Date:  1991-08-23       Impact factor: 3.252

3.  Origins and pathways of cerebrovascular nerves storing substance P and calcitonin gene-related peptide in rat.

Authors:  N Suzuki; J E Hardebo; C Owman
Journal:  Neuroscience       Date:  1989       Impact factor: 3.590

4.  Visualization of the vesicular acetylcholine transporter in cholinergic nerve terminals and its targeting to a specific population of small synaptic vesicles.

Authors:  E Weihe; J H Tao-Cheng; M K Schäfer; J D Erickson; L E Eiden
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

5.  Parasympathetic cerebrovascular innervation: an anterograde tracing from the sphenopalatine ganglion in the rat.

Authors:  H Hara; Q J Zhang; T Kuroyanagi; S Kobayashi
Journal:  Neurosurgery       Date:  1993-05       Impact factor: 4.654

6.  The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater.

Authors:  M G Buzzi; M A Moskowitz
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

7.  Accompanying symptoms of cluster attacks: their relevance to the diagnostic criteria.

Authors:  G Nappi; G Micieli; A Cavallini; C Zanferrari; G Sandrini; G C Manzoni
Journal:  Cephalalgia       Date:  1992-06       Impact factor: 6.292

8.  Cluster headache attacks treated for up to three months with subcutaneous sumatriptan (6 mg). Sumatriptan Cluster Headache Long-term Study Group.

Authors:  K Ekbom; A Krabbe; G Micieli; A Prusinski; J A Cole; A J Pilgrim; D Noronha; G ] Micelli G [corrected to Micieli
Journal:  Cephalalgia       Date:  1995-06       Impact factor: 6.292

9.  Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. The Sumatriptan Cluster Headache Study Group.

Authors:  K Ekbom; I Monstad; A Prusinski; J A Cole; A J Pilgrim; D Noronha
Journal:  Acta Neurol Scand       Date:  1993-07       Impact factor: 3.209

10.  Distribution of neuropeptides in rat pterygopalatine ganglion: light and electron microscopic immunohistochemical studies.

Authors:  H Motosugi; T Chiba; A Konno; T Kaneko
Journal:  Arch Histol Cytol       Date:  1992-12
View more
  10 in total

Review 1.  Is sinus disease the cause of my headaches? An update on sinus disease and headache.

Authors:  Larry Charleston; Richard Strabbing; Wade Cooper
Journal:  Curr Pain Headache Rep       Date:  2014-06

2.  CSD-Induced Arterial Dilatation and Plasma Protein Extravasation Are Unaffected by Fremanezumab: Implications for CGRP's Role in Migraine with Aura.

Authors:  Aaron J Schain; Agustin Melo-Carrillo; Jennifer Stratton; Andrew M Strassman; Rami Burstein
Journal:  J Neurosci       Date:  2019-05-24       Impact factor: 6.167

Review 3.  Pathophysiology of Migraine: A Disorder of Sensory Processing.

Authors:  Peter J Goadsby; Philip R Holland; Margarida Martins-Oliveira; Jan Hoffmann; Christoph Schankin; Simon Akerman
Journal:  Physiol Rev       Date:  2017-04       Impact factor: 37.312

Review 4.  Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.

Authors:  Jonathan Jia Yuan Ong; Diana Yi-Ting Wei; Peter J Goadsby
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

5.  Modulation of brain networks by sumatriptan-naproxen in the inflammatory soup migraine model.

Authors:  James Bishop; Lino Becerra; Gabi Barmettler; Pei-Ching Chang; Vanessa Kainz; Rami Burstein; David Borsook
Journal:  Pain       Date:  2019-09       Impact factor: 7.926

6.  A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).

Authors:  Roger K Cady; Peter J McAllister; Egilius L H Spierings; John Messina; Jennifer Carothers; Per G Djupesland; Ramy A Mahmoud
Journal:  Headache       Date:  2014-10-30       Impact factor: 5.887

7.  AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.

Authors:  Stewart J Tepper; Roger K Cady; Stephen Silberstein; John Messina; Ramy A Mahmoud; Per G Djupesland; Paul Shin; Joao Siffert
Journal:  Headache       Date:  2015-05-04       Impact factor: 5.887

8.  Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier.

Authors:  Rodrigo Noseda; Aaron J Schain; Agustin Melo-Carrillo; Jason Tien; Jennifer Stratton; Fanny Mai; Andrew M Strassman; Rami Burstein
Journal:  Cephalalgia       Date:  2019-12-19       Impact factor: 6.292

9.  Sphenopalatine ganglion block: an external gate to modulate cardiac autonomic tone and suppress premature ventricular beats?

Authors:  Dimitrios N Katsaras; Chrysa K Arvaniti; Panayota G Flevari; Georgios V Giannopoulos; Chrysanthi Z Batistaki; Vassilios E Stassinos; Georgia G Kostopanagiotou; Spyridon G Deftereos; Efstathios K Iliodromitis; Dionyssios I Leftheriotis
Journal:  Ann Transl Med       Date:  2018-12

Review 10.  New Insights on Metabolic and Genetic Basis of Migraine: Novel Impact on Management and Therapeutical Approach.

Authors:  Irene Simonetta; Renata Riolo; Federica Todaro; Antonino Tuttolomondo
Journal:  Int J Mol Sci       Date:  2022-03-11       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.